Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism

Ae Young Her, Jong Youn Kim, Seok Min Kang, Donghoon Choi, Yangsoo Jang, Namsik Chung, Ichiro Manabe, Sang Hak Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% ± 14%, P =.04) and the combination group (-46% ± 8%, P =.05) than in the atorvastatin group (-39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and -0.4% ± 4.0%, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.

Original languageEnglish
Pages (from-to)167-174
Number of pages8
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume15
Issue number2
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Apolipoprotein A-I
Apolipoproteins B
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
LDL Cholesterol
Glucose
Hemoglobins
Insulin Resistance
Homeostasis
Lipids
Atorvastatin Calcium
Ezetimibe
Rosuvastatin Calcium
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{970f809c9d564a58bce40aa1fb866824,
title = "Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism",
abstract = "The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47{\%} ± 14{\%}, P =.04) and the combination group (-46{\%} ± 8{\%}, P =.05) than in the atorvastatin group (-39{\%} ± 11{\%}). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0{\%} ± 5.2{\%} and -0.4{\%} ± 4.0{\%}, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.",
author = "Her, {Ae Young} and Kim, {Jong Youn} and Kang, {Seok Min} and Donghoon Choi and Yangsoo Jang and Namsik Chung and Ichiro Manabe and Lee, {Sang Hak}",
year = "2010",
month = "6",
day = "1",
doi = "10.1177/1074248409357922",
language = "English",
volume = "15",
pages = "167--174",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "2",

}

Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. / Her, Ae Young; Kim, Jong Youn; Kang, Seok Min; Choi, Donghoon; Jang, Yangsoo; Chung, Namsik; Manabe, Ichiro; Lee, Sang Hak.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 15, No. 2, 01.06.2010, p. 167-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism

AU - Her, Ae Young

AU - Kim, Jong Youn

AU - Kang, Seok Min

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Chung, Namsik

AU - Manabe, Ichiro

AU - Lee, Sang Hak

PY - 2010/6/1

Y1 - 2010/6/1

N2 - The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% ± 14%, P =.04) and the combination group (-46% ± 8%, P =.05) than in the atorvastatin group (-39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and -0.4% ± 4.0%, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.

AB - The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% ± 14%, P =.04) and the combination group (-46% ± 8%, P =.05) than in the atorvastatin group (-39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and -0.4% ± 4.0%, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.

UR - http://www.scopus.com/inward/record.url?scp=77951887479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951887479&partnerID=8YFLogxK

U2 - 10.1177/1074248409357922

DO - 10.1177/1074248409357922

M3 - Article

C2 - 20147603

AN - SCOPUS:77951887479

VL - 15

SP - 167

EP - 174

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 2

ER -